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Abstract 
Objectives: In vivo evaluations of a gonadotropin releasing hormone‑receptor single photon emission computed 
tomography radiotracer for non‑invasive detection of gonadotropin releasing homone‑receptors in brain.
Results: We have used a simple, robust and high‑yielding procedure to radiolabel an alpha‑halogenated bioactive 
compound with high radiochemical yield. Literature findings showed similar alpha‑halogenated compounds suitable 
for in vivo evaluations. The compound was found to possess nano molar affinity for the gonadotropin releasing hor‑
mone‑receptor in a competition dependent inhibition study. Furthermore, liquid chromatography‑mass spectrometry 
analysis in saline, human and rat serum resulted in 46%, 52% and 44% stability after incubation for 1 h respectively. 
In addition, rat brain single photon emission computed tomography and biodistribution studies gave further insight 
into the nature of the compound as a radiotracer.
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Introduction
Disturbance of gonadotropin releasing hormone (GnRH) 
signaling is implied in a variety of human diseases span-
ning from reproductive diseases, hormone dependent 
oncological diseases and neurodegenerative diseases. 
GnRH receptor (GnRH-R) play a central role in this con-
text and have consequently attracted considerable inter-
est as therapeutic targets [1, 2].
Novel single photon emission computed tomography 
(SPECT) and positron emission tomography (PET) radi-
otracers for imaging are of high importance in diagnos-
tic medicine. This is linked to the necessity of advances 
in radiochemistry and radiobiology development [3]. The 
aim of the present study is to develop a GnRH-R SPECT 
radiotracer to allow for non-invasive detection of GnRH-
R in brain in vivo.
We have previously disclosed the discovery of GnRH-
R antagonists and a thorough mechanistic analysis of 
halogen exchange by the use of anchimeric assistance 
by amide groups [4]. In addition, Compound-1 has been 
radiolabeled in high radiochemical yield [5]. Alpha-
halogenated compounds are widely used in organic 
chemistry, medicinal chemistry and radiochemistry as 
prosthetic groups and for further diversification of lead 
molecules [6, 7]. Little is published on alpha-halogenated 
amides as possible radiotracers. A possible explanation 
may be due to the relatively high reactivity normally 
observed in such systems [8]. Nevertheless, Legros et al. 
investigated the molecular pharmacology of melatonin 
receptors with alpha halogenated amides. They reported 
compounds SD6 and S70254 (Fig.  1a) which contain 
alpha-iodide next to an amide group. Compounds SD6 
and S70254 were 125I-labeled and their receptor speci-
ficity evaluated by cell membrane binding assays, tissue 
membrane saturation assays and in vitro autoradiography 
of brain and retina from rat and sheep [9, 10].
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In light of this literature reference, our focus turned to 
a further evaluation of Compound-1 as a potential can-
didate for in vivo brain GnRH-R SPECT imaging studies 
despite its alpha-halogen motif.
Main text
Materials and methods
All solvents and reagents were obtained from Sigma 
Aldrich (Sigma-Aldrich Norway AS) except  Na123I (GE 
Healthcare, Netherlands). Rat and human sera were 
kindly donated by the Vascular Biology research group 
at UiT-The Arctic University of Norway. The semi-pre-
parative radio-HPLC (High Performance Liquid Chro-
matography) consists of a DIONEX HPLC-system, 
HPLC-pump P680 with a PDA detector (PDA-100) 
with  XBridge® prep C18 5 µm  OBDtm 19 × 250 nm col-
umn and a radioactivity flow detector for HPLC LB 509 
(Berthold technologies, Germany). The LC–MS (Liquid 
Chromatography Mass Spectroscopy) is a Thermo scien-
tific LTQ Orbitrap XL, ESI-ionmax (Germany).
Male Wistar Han IGS rats of 6–9 weeks age were pur-
chased from Charles River (Germany). The animals 
were housed in the Department of Comparative Medi-
cine at UiT-The Artic University of Norway. The ani-
mals had access to water and standard chow (Scanbur, 
BK, Norway) ad  libitum. All experimental protocols 
were approved by The Norwegian Food Safety Author-
ity and conducted in accordance to the Norwegian law, 
FOR-2017-04-05-451.
The key intermediate 1a and Compound-1 were pre-
pared according to literature procedures [4, 11]. In brief, 
non carrier added  Na123I was prepared in a concentra-
tion step over 4 h evaporating the solvent.  Na123I reacted 
with 1a in acetone for 1 h in reflux (Fig. 1b). The fractions 
were collected and the solvents evaporated. Products 
were confirmed by radio-HPLC.
The stability of Compound-1 was initially inves-
tigated in saline. Compound-1 was dissolved in 
ethanol:Polysorbate 80:water (5:5:90) then incubated 
with 300  µl 0.9% NaCl at ambient temperature to give 
a final concentration of 6.5  mM (millimolar). Ali-
quots were taken at 0, 60, 120 and 1560 min, then ana-
lysed by LC–MS. Furthermore, Compound-1 was 
investigated in human and rat serum. Compound-1 in 
ethanol:Polysorbate 80:water (5:5:90) was incubated with 
400 µl human and 300 µl rat serum at 37 °C to give a final 
concentration of 5 mM and 6.5 mM. Aliquots (40–50 µl) 
from previous mixtures was extracted with ice-cold ace-
tonitrile at 0, 10, 30, 60, 120, 240 and 1320 min post-incu-
bation. Samples were centrifuged at 13,000g for 5  min. 
The supernatants were analysed by LC–MS. Serum 
experiments were performed in triplicate. Additionally, 
 [123I]-Compound-1 was evaluated for in  vivo stability 
by analyzing blood samples after 1 h post injection. The 
blood samples were centrifuged and the supernatant was 
injected on the radio-HPLC.
HEK293T (division arrested cell-line, Multispan Inc. 
USA) cells stably expressing GnRH receptors were used 
to measure the competitive binding for LHRH/GnRH 
by a fluorescence based FLIPR-assay [12]. Compound-1 
was tested in concentrations from 50 µM to 0.5 nM with 
5  nM LHRH agonist as competitor. The commercially 
available compound WAY207024 was included as a ref-
erence compound since it has a known affinity for the 
GnRH-R.
Compound-1 SPECT brain imaging and biodistri-
bution were examined post injection in rats. All ani-
mal procedures were performed under isoflurane 
anesthesia (Induction 4%, Maintenance 2% in oxygen). 
One group of rats was injected intravenous (iv.) with 
 [123I]-Compound-1 (1.67  MBq ± 0.28, n = 3). A second 
group was injected intraperitoneal (ip.) (4.12 MBq ± 0.56, 
n = 3). A third group of animals was injected iv. with 
Fig. 1 a Different alpha‑halogenated molecules for imaging 
purposes [9, 10]. b Reaction scheme for the radiolabeling of 
Compound‑1 by using  Na123I c) Competitive binding in competition 
of 5 nM LHRH agonist. Compound‑1(C1) was evaluated in 
comparison with reference compound WAY207024. Compound‑1 
have an nM affinity for the GnRH‑R and show only a drop of 
magnitude in affinity compared to WAY207024
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 Na123I (1.53  MBq ± 0.37 SD, n = 3). Biodistribution of 
these compounds was studied after the SPECT imag-
ing sessions 1  h post-injection (in the iv. groups) and 2 
and 5  h post-administration in the ip. group. Rats were 
positioned with the brain in the center of the field of view 
inside a 4 detector configuration Triumph™ II X-SPECTⓇ 
small animal PET/SPECT/CT scanner (Trifoil Imag-
ing, Northridge Tri-Modality Imaging, Inc., Chatsworth, 
CA). Heart rate and breathing was monitored with sen-
sors inside a closed animal cell (Equipment Veterinaire 
Minerve, Esternay) and the temperature on the heated 
air flow inside the cell was set to 35 °C to prevent hypo-
thermia. Dynamic SPECT acquisitions for 30 and 60 min 
with 6–12 image frames (5 min duration) were obtained 
for the animals which were used for 1–2  h biodistribu-
tion studies respectively. The animals subjected to the 
5  h biodistribution study were scanned after an aver-
age of 4  h and 20  min, a static SPECT of 30  min was 
acquired. 1.0 mm 5-multipinhole collimator (N5F65A10) 
and 50 mm radius of rotation (ROR). Images were recon-
structed using a 20% energy window and Ordered Subset 
Expectation Maximization (OSEM) algorithm with 5 iter-
ations and 8 subsets. Computed tomography (CT) was 
performed using 80 kVp, 2 × 2 binning, 512 projections 
and 1.3× magnification, immediately after SPECT imag-
ing. The raw data were reconstructed using Filtered Back 
Projection. Images were analyzed using PMOD (PMOD 
Technologies Ltd., Zürich). Volumes of interests (VOI) 
representing the brain-tissue, non-brain-tissue and back-
ground regions were delineated based on the anatomical 
CT images, and transferred to the co-registered dynamic 
SPECT data. In addition, an average SPECT image over 
all time frames was calculated for each animal.
Animals were euthanized with an overdose of pento-
barbital (ip. 100  ml/kg) and organs were collected, 
weighed and analysed for radioactivity measurements 
on an automatic gamma counter  (Wizard2 2480, Perkin 
Elmer, USA). Organ distribution was expressed as per-
centage of injected dose per gram for the organs selected 
(% ID/g).
Results
Stability test in saline revealed that 46% of the com-
pound remained after 1 h incubation, decreasing to 10% 
after 2  h and to 2% 24  h post incubation (Additional 
file 1: Table S1). Human and rat serum stability analyses 
performed by LC–MS showed a 50% decrease of Com-
pound-1 after 1 h. After 2 h incubation, 23% of the com-
pound remained in human serum and approximately 30% 
in rat serum. The blood samples which where analyzed 
by radio-HPLC after 1  h post injection did not detect 
 [123I]-Compound-1.
The concentration dependent competition study 
using HEK293T cell lines and LHRH agonist showed 
that Compound-1 presented  pIC50 of 5.29. The Ki was 
determined by using the cheng-prusoff equation [13]. 
Compound-1 was found to have a  Ki value of 82.0  nM 
compared to 12.2 nM for the commercially available ref-
erence WAY207024 (Fig.  1c). The antagonist affinity of 
Compound-1 dropped approximately one order of mag-
nitude compared to WAY207024.
The SPECT ratios for the VOIs brain vs non-brain 
and brain vs background were statistically analyzed and 
showed no significant difference (Fig. 2a, b). The SPECT 
images showed no uptake in the rat brain at the doses 
injected regardless of the administration mode (Fig. 2c).
Biodistribution analyses revealed that most of the activ-
ity for  [123I]-Compound-1 was distributed in the stomach 
3.6% ID/g and the thyroid 1.2% ID/g. The uptake in tes-
tis and brain was 0.2% ID/g and 0.03% ID/g respectively. 
Similarly, a high  Na123I uptake was presented in the thy-
roid (3.6% ID/g) and stomach (3.4% ID/g) (Fig.  3a). The 
biodistribution examined 2  h and 5  h post ip. adminis-
tration of  [123I]-Compound-1 revealed high uptake in the 
thyroid 5.8% ID/g after 2 h and even higher uptake after 
5  h (13.1% ID/g). By comparison, the stomach showed 
2.5% ID/g after 2 h and 2% ID/g after 5 h (Fig. 3b). Thy-
roid uptake was also observed in the SPECT images in all 
animal groups (Fig. 2c).
Discussion
The GnRH-R plays a crucial role in several diseases and 
it is located within and outside the brain [1, 2, 14, 15]. 
Beside the CNS, the GnRH-R is also expressed in the 
Hypothalamus–pituitary–gonadal axis (HPG axis) (e.g. 
breast, endometrium, ovary, and prostate) and tumors 
derived from these tissues [1]. In addition, GnRH-R 
are found in other sites, such as: kidney, liver and heart 
[15]. Our aim was to target the GnRH-R in the CNS by 
SPECT imaging since quantifying GnRH-R expression 
will give valuable information for diagnosis, treatment 
and pathophysiology. We have previously disclosed the 
radiolabelling of Compound-1 using an acylation-Fin-
kelstein approach in 80% analytical RCY and 17% iso-
lated yield [4]. This gave us a straightforward access to 
the radioiodinated compound which is in compliance 
with requirements for radiolabelling [16]. The affinity 
to the GnRH-R was evaluated in a competitive binding 
assay. Compound-1 showed nanomolar (nM) affinity 
 (Ki = 82 nM) to the GnRH-R compared to the reference 
compound WAY207024 [17]. The stability of alpha-halo-
genated Compound-1 was a concern due to its reactivity 
and could therefore not be suitable for physiological con-
ditions. However, literature findings showed precedence 
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for assessment of such compounds (SD6 and S70254) 
with alpha-halogenated amides labelled with 125I [9, 10].
Serum stability analysis is an initial step in the in vitro 
evaluation [18]. Compound-1 revealed sufficient stabil-
ity for imaging following incubations in saline, rat and 
human serum. Competitive binding studies in H293T 
cells presented Compound-1 binding affinities for human 
GNRH-R in the nM range. These indications favored the 
biodistribution studies of Compound-1 in rats and, fur-
thermore, the in vivo evaluation as a potential GnRH-R 
SPECT imaging agent.
A semi-quantitative SPECT analysis was established 
to evaluate the  [123I]-Compound-1 brain uptake. Three 
VOIs (brain, non-brain region and a background 
region) were defined and compared to each other with 
no significant differences. The SPECT images presented 
no uptake of the Compound-1 in rat brain. Similar iv. 
injection doses were reported in previous preclini-
cal evaluation of  [123I]-labeled compounds [19]. Com-
pound-1 ip. administration was evaluated as well since 
it will be delivered slower to the circulation compared 
to iv. injections and therefore a different biodistribu-
tion could be achieved [20]. However, no differences 
were observed in the iv. group compared to the ip. 
group. In addition, comparison of the biodistribution of 
 [123I]-Compound-1 with  Na123I revealed no differences. 
After injection of  [123I]-Compound-1, the activity was 
mainly distributed in the thyroid and the stomach, sug-
gesting the rapid deiodination of Compound-1. We 
observed similar  [123I]-Compound-1 and  Na123I uptake 
patterns in brain and testis, where GnRH-R is known 
to be expressed, indicating that the activity is due to 
the presence of free 123I- in these regions [15]. To our 
knowledge, no reports of the  Na123I biodistribution are 
available for male Wistar rats. However, the biodistri-
bution of free 125I- and 131I- for male Sprague–Dawley 
rats is known [21]. The uptake of free 123I- corresponds 
to a large degree of the previously reported biodistribu-
tion patterns of 125I- and 131I. Additionally, blood sam-
ples analyzed 1 h post injection by radio-HPLC did not 
detect  [123I]-Compound-1 which may be explained by 
the rapid deiodination.
Despite our predictions of the reactive nature of 
alpha-halogenated amides, Compound-1 was sta-
ble long enough for a sufficient in  vivo validation. The 
compound was initially validated in saline, human and 
rat serum. No differences were shown in the analy-
sis of brain SPECT images and biodistribution stud-
ies of the  [123I]-Compound-1 compared to  Na123I. 
Compound-1 did not show any uptake in the brain 
despite the promising stability and previous literature 
data.  [123I]-Compound-1 is therefore not suitable as a 
brain SPECT-radiotracer and further evaluation of the 
in vivo stability by e.g. metabolic profiling will reveal its 
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Fig. 2 [123I]‑Compound‑1 rat brain SPECT evaluation. a CT image showing the brain (blue), non‑brain (green) and background (yellow) VOIs. b 
Comparison of the intensity ratios between brain and non brain VOIs and brain and background VOIs of  [123I]‑Compound‑1 (orange bars) and 
 Na123I (white bars) intravenously injected animals. Results are expressed as mean ± SD (n = 3). c Sagittal rat head SPECT‑CT fused images. SPECT‑CT 
of an animal intravenously (iv.) injected with  Na123I (left panel) and [123I]‑Compound‑1 (middle panel). Right panel shows a SPECT‑CT of a rat 
intraperitoneally (ip.) injected with  [123I]‑Compound‑1. Images were produced after averaging all the acquisition time frames. Images are displayed 
at different intensity scales
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suitability as a radiotracer outside the CNS in tissues 
where GnRH-R are located such as the HPG axis, tumors 
derived from these tissues and in liver, kidney and heart.
Limitations
Indications that the Compound-1 is not suitable as a 
clinical SPECT radiotracer are evident in the present 
study. However, evaluation of the Compound-1 distri-
bution at shorter time points (1–5 min) post-injection 
could have been tested avoiding deiodination at early 
time points. In addition, further studies for similar 
compounds with longer chain lengths and fluorine or 
fluorine-18 for future PET are planned and our chemi-
cal kinetics experiments indicate far more robust com-
pounds in this series [4].
Additional file
Additional file 1: Table S1. Stability of Compound‑1 in human and rat 
serum and saline. Results are expressed as % of compound remaining 
in serum of human and rat samples as well as saline after the different 
incubation time points. Mean ± SD (n = 3). an = 1. Figure S1.  IC50 curves 
for Compound‑1 in a competition dependent study for affinity to the 
GnRH‑receptor.
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Fig. 3 [123I]‑Compound‑1 rat biodistribution. a Organ distribution of 
 Na123I (white bars) and  [123I]‑Compound‑1 (orange bars) 1 h post iv. 
injection in rats. b Organ distribution of  [123I]‑Compound‑1 2 h (white 
bars) and 5 h (orange bars) post intraperitoneal (ip.) injection in rats. 
Results are expressed as % injected dose (ID)/g tissue. Mean +SD 
(n = 3). Bl, blood; H, heart; Lu, lungs; Li, liver; Sp, spleen; Pa, pancreas; 
St, stomach; SIn, small intestine; LIn, large intestine; K, kidneys; Td, 
thyroid; Tm, thymus; Bo, bone; Mu, muscle; F, fat; Ts, testis; Br, brain
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